S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
The Market Crash Shield is A.I. (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
The Market Crash Shield is A.I. (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
The Market Crash Shield is A.I. (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
The Market Crash Shield is A.I. (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
The Market Crash Shield is A.I. (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
The Market Crash Shield is A.I. (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
The Market Crash Shield is A.I. (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
The Market Crash Shield is A.I. (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
NASDAQ:FWBI

First Wave BioPharma - FWBI Stock Forecast, Price & News

$2.68
+0.08 (+3.08%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.59
▼
$2.87
50-Day Range
$2.49
▼
$5.86
52-Week Range
$2.49
▼
$289.80
Volume
29,417 shs
Average Volume
77,467 shs
Market Capitalization
$4.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

First Wave BioPharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
5,273.1% Upside
$144.00 Price Target
Short Interest
Healthy
4.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.22) to ($2.87) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

See Top Rated MarketRank™ Stocks Here

FWBI stock logo

About First Wave BioPharma (NASDAQ:FWBI) Stock

First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.

Receive FWBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for First Wave BioPharma and its competitors with MarketBeat's FREE daily newsletter.

FWBI Stock News Headlines

March 13, 2023 | finance.yahoo.com
First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
March 10, 2023 | msn.com
FWBI Rises on First Patient Dosing in Cystic Fibrosis Trial
April 2, 2023 | Vantage Point (Ad)
Did You See These Trend Reversals?
Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. pixel
March 10, 2023 | finance.yahoo.com
First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis
March 9, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Their Buy Rating for First Wave Bio (FWBI)
March 9, 2023 | finance.yahoo.com
First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
February 21, 2023 | finance.yahoo.com
First Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) Conference
February 19, 2023 | benzinga.com
First Wave BioPharma, Inc. (NASDAQ: FWBI) Featured in Coverage of the 35th Annual Roth Conference
April 2, 2023 | Vantage Point (Ad)
Did You See These Trend Reversals?
Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. pixel
February 7, 2023 | finance.yahoo.com
First Wave BioPharma Regains Compliance With Nasdaq’s Minimum Bid Price Requirement
February 2, 2023 | finance.yahoo.com
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis
January 31, 2023 | finance.yahoo.com
First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis
January 30, 2023 | finance.yahoo.com
First Wave BioPharma to Present at the BIO CEO & Investor Conference
January 25, 2023 | nasdaq.com
First Wave Climbs On Expansion Of Adrulipase IP Portfolio
January 25, 2023 | investorplace.com
Why Is First Wave BioPharma (FWBI) Stock Up 30% Today?
January 25, 2023 | finance.yahoo.com
First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio
January 25, 2023 | finance.yahoo.com
First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio
January 24, 2023 | finance.yahoo.com
First Wave BioPharma to Present at Sequire Biotechnology Conference
January 16, 2023 | nasdaq.com
First Wave (FWBI) IND Filing Under FDA's Review, Stock Up
January 16, 2023 | msn.com
First Wave BioPharma says IND amendment for adrulipase is under FDA review
January 13, 2023 | markets.businessinsider.com
First Wave BioPharma Jumps 25% On Update Of Adrulipase IND Filing
January 13, 2023 | finance.yahoo.com
First Wave BioPharma Provides Update on IND Filing For Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency
January 13, 2023 | finance.yahoo.com
First Wave BioPharma Announces Results of Special Meeting of Stockholders
January 9, 2023 | finance.yahoo.com
First Wave BioPharma Announces Adjournment of Special Meeting
January 5, 2023 | finance.yahoo.com
ZyVersa Therapeutics Appoints Three New Board Members
December 12, 2022 | finance.yahoo.com
First Wave BioPharma to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2023”
November 30, 2022 | finance.yahoo.com
First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase
See More Headlines
Receive FWBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for First Wave BioPharma and its competitors with MarketBeat's FREE daily newsletter.

FWBI Company Calendar

Last Earnings
11/14/2021
Today
4/01/2023
Next Earnings (Estimated)
5/22/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FWBI
CUSIP
N/A
CIK
1604191
Web
www.azurrx.com
Phone
(561) 589-7020
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$144.00
High Stock Price Forecast
$270.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+571.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,630,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-256.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.37
Quick Ratio
1.37

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.76 per share
Price / Book
0.97

Miscellaneous

Outstanding Shares
1,550,000
Free Float
1,544,000
Market Cap
$4.15 million
Optionable
Not Optionable
Beta
1.62

Key Executives

  • James E. Sapirstein
    Chairman, President & Chief Executive Officer
  • Sarah M. Romano
    Chief Financial Officer
  • Amy Chandler
    VP-Regulatory Affairs, QA & Compliance
  • Martin Krusin
    Senior VP-Corporate Development
  • Loreal McDonald
    General Counsel

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













FWBI Stock - Frequently Asked Questions

Should I buy or sell First Wave BioPharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for First Wave BioPharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FWBI shares.
View FWBI analyst ratings or view top-rated stocks.

What is First Wave BioPharma's stock price forecast for 2023?

2 brokerages have issued 1 year price targets for First Wave BioPharma's shares. Their FWBI share price forecasts range from $18.00 to $270.00. On average, they predict the company's stock price to reach $144.00 in the next twelve months. This suggests a possible upside of 5,273.1% from the stock's current price.
View analysts price targets for FWBI or view top-rated stocks among Wall Street analysts.

How have FWBI shares performed in 2023?

First Wave BioPharma's stock was trading at $0.8756 at the beginning of 2023. Since then, FWBI stock has increased by 206.1% and is now trading at $2.68.
View the best growth stocks for 2023 here.

When is First Wave BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 22nd 2023.
View our FWBI earnings forecast.

How were First Wave BioPharma's earnings last quarter?

First Wave BioPharma, Inc. (NASDAQ:FWBI) posted its quarterly earnings data on Sunday, November, 14th. The company reported ($98.10) earnings per share for the quarter, missing analysts' consensus estimates of ($23.70) by $74.40.

When did First Wave BioPharma's stock split?

Shares of First Wave BioPharma reverse split on Friday, August 26th 2022. The 1-30 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What is First Wave BioPharma's stock symbol?

First Wave BioPharma trades on the NASDAQ under the ticker symbol "FWBI."

How do I buy shares of First Wave BioPharma?

Shares of FWBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is First Wave BioPharma's stock price today?

One share of FWBI stock can currently be purchased for approximately $2.68.

How much money does First Wave BioPharma make?

First Wave BioPharma (NASDAQ:FWBI) has a market capitalization of $4.15 million.

How can I contact First Wave BioPharma?

First Wave BioPharma's mailing address is 760 Parkside Ave Ste 304, Brooklyn, New York 11226-1784. The official website for the company is www.azurrx.com. The company can be reached via phone at (561) 589-7020 or via email at investors@azurrx.com.

This page (NASDAQ:FWBI) was last updated on 4/2/2023 by MarketBeat.com Staff